Herein we describe the use of intracavernous methylene blue (MB), a guanylate cyclase inhibitor, or internal pudendal artery embolization for the treatment of priapism. Eleven patients with priapism were treated from 1993±1996. Etiologies of priapism included PGE 1 /papaverine (3), trazodone (2), and sickle cell disease (1), in the other ®ve cases the cause was unknown. The average duration of priapism was 27 h for all patients (6±72 h). Five patients who failed intracavernous MB or an a-adrenergic agonist, underwent unilateral or bilateral pudendal artery embolization. The average duration of priapism for patients undergoing embolization was 43 h.
Introduction
Over the last decade advances in understanding the physiology and pharmacology of erection have led to greatly expanded knowledge of the etiology and treatment of priapism. 1 Pharmacologically-mediated priapism is more common with the widespread use of intracavernous (IC) therapy for impotence. This adverse event is treated by (IC) a-adrenergic agonists such as phenylephrine. 2 The search for other nonsurgical treatments with minimal systemic side effects has led us to investigate the use of methylene blue. 3 Neurally-mediated vasodilatation and corporal cavernosal smooth muscle relaxation produce tumescence. 1 Nitric oxide (NO) released from parasympathetic nerves activates a guanylate cyclase which leads to elevation of cGMP.
4±6 GTP or ATP is converted to its cyclic monophosphate moieties, which is thought to produce a fall in cytosolic calcium causing relaxation of smooth muscle. Methylene blue (MB) is an inhibitor of guanylate cyclase and thereby blocks the smooth muscle relaxation initiated by nitric oxide (NO) or other agents which cause a rise in cGMP. We have previously reported temporary success with IC methylene blue for the treatment of priapism. 3 Methylene blue is widely used topically and intravenously. Its has virtually no signi®cant side effects and is rapidly excreted by the kidneys into the urine. Rarely, a slight rise in blood pressure is seen after systemic administration. The safety pro®le of MB and its ability to block the effects of nitrovasodilators including NO lead to its routine use in the treatment of priapism. As an inhibitor of guanylate cyclase, MB is hypothesized to produce detumescence by preventing prolonged activation of a cGMP pathway. It may also release norepinephrine via free radical formation.
Despite the widespread use of a-adrenergic agonists for priapism, surgical management is often necessary. The Winter 7, 8 percutaneous procedure and the Al-Ghorab or Quackles shunts are commonly performed. The success rates for these procedures vary from 50±65%. 8, 9 Wear et al. 10 ®rst described the treatment of priapism with pudendal artery embolization in 1977. In an effort to avoid surgery, which lacks ef®cacy in at least half of the patients, we prospectively subjected all cases of priapism refractory to IC MB or an a-adrenergic agonist to pudendal embolization to see if results were comparable to surgery. The goal of this study was to describe and compare two new non-surgical treatment regimens for priapism.
Methods
Eleven patients were treated for priapism between 1993 and 1996. The age range was 22±56 y (mean 37 y). The average duration of priapism for the entire group was 7 h (range 6±72 h). Priapism was de®ned as prolonged painful tumescence lasting more than 6 h. Etiology for patients were: PGE 1 (n 2), trazodone (n 2), papaverine (n 1), sickle cell (n 1) and idiopathic (n 5). Five patients were treated initially at our institution. The remaining six men were referred after unsuccessful treatments by community urologists. In patients without previous therapy. MB was ®rst administered after irrigation and aspiration of the copora. Approximately 50 mg of MB 1/2 ampule) was injected IC and left for 3± 5 min. The MB was then aspirated and light compression was held on the penis for 5 min. MB was administered after aspiration of the blood from the copora cavernosa. Two of the 11 were not given MB due to previous extensive surgery for their priapism. These patients underwent immediate unilateral pudendal artery embolization. Because nearly half the patients presented after lengthy delays with substantial penile edema, effective therapy in these patients was de®ned as a greater than 50% detumescence and relief of pain.
Patients receiving pudendal artery embolization underwent diagnostic arteriography of the pelvis with bilateral selective injections of the internal pudendal arteries. No arterio-venous ®stulas or arterial extravasation was identi®ed. Embolization was performed through a 5F multi-purpose catheter (Cook, Bloomington, IN), advanced to the distal internal pudendal artery or to the level of the common penile artery. In patients with small caliber pudendal arteries, a 3F microcather (Target Therapeutics, Fremont, CA) was placed coaxially through the 5F catheter. Approximately 1 mm Â 1 mm62 mm pledgets of Gel-Foam (Upjohn Cio, Kalamazoo, MI) were injected until complete stasis was achieved. Embolization was bilateral in four of ®ve cases. Staged procedures were separated by 24 h to monitor for detumescence and skin necrosis.
All patients had bright red blood (BRB) aspirated from the corpora during initial treatment. All Figure 1 Site of action for methylene blue. Corpus cavernosum smooth muscle relaxation can be achieved by nitric oxide acting on guanylate cyclose thereby producing a rise in cGMP. Likewise, PGE 1 acting on adenylate cyclse can raise cAMP. cAMP is normally degraded by a phosphodiesterase (probably type 3). Elevations in these cyclic nucleotides cause relaxation. Papaverine may enhance relaxation and erections by inhibiting a phosphodiesterase. Figure 2 Results of intracavernous methylene blue on priapism. Success after methylene blue is de®ned as complete detumescence and pain relief. patients underwent angiographically demonstrated dilation of the pudendal artery. An attempt was made to call each of these patients after one year.
Results
Nine patients were treated with MB. If MB was ineffective then phenylephrine was administered. However, no patient failing MB was effectively rescued with an a-adrenergic agonist. Six of nine (67%) patients were cured using MB alone. For drug induced priapism, 100% of the patients were cured with MB alone. In contrast, only 20% of the idiopathic patients were cured with MB, with an average duration of priapism of 42 h. The primary side effect was transient mild burning with injection of the MB.
Five patients who failed prior IC therapy and/or surgical shunt procedures underwent embolization of the pudendal artery. None of these patients gave a history of trauma to the perineum or penis. The average duration of priapism in this refractory group was 43 h. All patients in the embolization series had aspiration of bright red blood from the corpora. Dilatation of the pudendal artery and the distal cavernous artery was seen on arteriography. In one patient unilateral embolization failed to elicit detumescence but provided relief from pain. This patient did not desire additional treatment. Two of the four remaining patients achieved detumescence after bilateral embolization. Adverse effects from the embolization were limited to gluteal pain.
Only ®ve of 11 patients were available for followup at one year after treatment. Of three patients who were cured by MB, all reverted to their baseline erectile status. One patient who had bilateral embolization had regained potency. Another patient with priapism lasting ten days remained impotent. Three patients died of unrelated causes. The remaining two patients could not be located.
Discussion
Management of priapism is problematic. While initial therapy with intracavernous vasoconstrictor agents is recommended, the roles of surgery and embolization are unclear. Methylene blue was a safe and effective treatment for priapism. The etiology and duration of priapism were the strongest predictors of success with intracavernous MB. The lack of ef®cacy of MB in patients failing previous therapies did not preclude success if administered early in the course of priapism. MB caused detumescence in patients with priapism following intracavernous prostaglandin E-1, suggesting interference with cAMP mechanisms.
Although MB appeared to be without signi®cant side effects in our series, penile necrosis has been reported after its used. 11 Necrosis has been attributed to free radical generation and tissue ischemia. However, this reported adverse event occurred in a patient who had 5 y of intermittent priapism with ®brosis, and occurred one week following an unsuccessful shunt procedure. In addition, the reported patient received intracavernous a-agonists. Alpha-agonists have been used after MB injection without ill effect, but this should be done with caution. Alpha-agonists offered no bene®t in cases where MB was unsuccessful. Apparently, either MB or a-agonists can be used as initial therapy, but if either is unsuccessful, additional bene®t from the other is unlikely. An additional side effect of MB treatment was a temporary blue discoloration of the penis. Two patients with priapism due to PGE complained of burning sensations of the penis following injection of MB, which resolved in 1 h. Within 1 year after successful MB treatment, three patients regained baseline erectile status. Oral agents such as a-agonists can be considered, but recent concerns regarding hypertension and cardiac arrhythmias may limit their usage. It is unknown whether oral MB would be effective.
If pharmacologic therapy fails, the decision whether patient should undergo a shunt procedure or pudendal artery embolization is unclear. A reported 50% failure rate for surgery prompted us to evaluate the use of pudendal artery embolization. There have been 22 previously reported cases of pudendal artery embolization for the treatment of priapism. 3,10,12±28 Authors recommend the use of embolization for`high¯ow priapism' attributed to trauma or A-V ®stulas. In these situations, nearly 100% ef®cacy with unilateral or bilateral embolization has been reported. However, the classi®cation of high and low¯ow priapism is problematic and embolization has been effective in`low¯ow rates'. 3, 16 Arteriography revealed dilation of internal pudendal arteries in all of our cases. The corporal aspirate, even if initially dark venous blood, eventually became bright red with continued aspiration. It can be speculated that once priapism develops, vasodilation continues due to ischemia, acidosis or hypoxia.
Embolization was performed in ®ve patients failing medical therapy, the results were poor. Bilateral treatment was necessary to achieve detumescence, but required 4±10 days. Without an untreated control group it is unclear whether similar results would have been obtained without therapy. Nevertheless, immediate pain relief was achieved and remains the primary indication for this approach. One of the two patients cured by bilateral embolization was able to obtain normal erections within six months following arteriography. Presumably, this patient either had recanalization of the internal pudendal arteries or generous collateral supply from the external pudendal branch of the femoral artery. Indeed, the failure of bilateral pudendal embolization to eradicate priapism may be explained on the basis of collateral blood¯ow through this external pudendal artery via the femoral artery. Repeat pudendal arteriography has been performed one year after a patient has successful treatment with Gelfoam embolization at our institution. This patient presented with recurrent priapism. The repeat arteriogram revealed recanalization of the distal pudendal artery. We believe patients having renal allografts, aortofemoral or femoral bypass surgery should not undergo pudendal artery embolization.
Conclusions
MB is an effective and safe treatment for priapism. This approach is best for drug-induced priapism of short duration. If drug therapy for priapism fails, pudendal artery embolization can be considered although shunt surgery may be contemplated. If priapism has been present for several days, it is unlikely that any therapy will be effective. The impotence rates for shunt therapy approach 50%, and appear to be related to the etiology and age of the patient. Return of potency with MB and bilateral pudendal artery embolization has been observed.
